Lycia Therapeutics
PrivateLast Round
Series D
Jun 25, 2026
Total Funding Raised
$301.6M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Lycia Therapeutics is a biotechnology company that discovers and develops first-in-class therapeutics using a lysosomal targeting chimeras platform to degrade extracellular and membrane-bound proteins associated with challenging diseases like cancers and autoimmune conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lycia Therapeutics Comparables
Compare Lycia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plexium | 87% | |
| Avilar Therapeutics | 85% | |
| Amphista Therapeutics | 82% | |
Lycia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 25, 2026 | ||||
| Series C | May 13, 2024 | ||||
| Series B | Sep 9, 2021 | ||||
| Series A | Jun 9, 2020 |
Lycia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series B |
| Owl Rock Capital Group | Series C |
| Janus Henderson Group | Series C, Series D |
| Balyasny Asset Management L.P. | Series D |
| Franklin Advisers | Series C |
| Franklin Templeton | Series D, Series C |
| TD Securities | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
$75M round led by Balyasny Asset Management and Janus Henderson.
- Feb 7, 2025
Chin Lee, M.D., M.P.H. appointed as new chief medical officer.
Lycia Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Lycia Therapeutics's valuation, stock price, and market status.